All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Vascular endothelial growth factor (VEGF) was identified and isolated as an endothelial cell-specific mitogen that has the capacity to induce physiological and pathological angiogenesis. It is a homodimeric glycoprotein with a molecular weight of approximately 45 kDa. It is the key mediator of angiogenesis (the formation of new blood vessels), and binds two VEGF receptors, which are expressed on vascular endothelial cells. In healthy humans, VEGF promotes angiogenesis in embryonic development and is important in wound healing in adults. VEGF is the key mediator of angiogenesis in cancer, in which it is up-regulated by oncogene expression, a variety of growth factors and also hypoxia.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-LC367 | Anti-VEGFA×ERBB2 h(CD3ζ/CD28) Dual CAR, pCDCAR1 | Human | XHM557 | Human | Lentiviral | T cell | |||
CAR-YF688 | Anti-VEGF (XHM557) h(CD3ζ) CAR, pCDCAR1 | Human | XHM557 | Mouse | scFv-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF690 | Anti-VEGF (219R45) h(CD3ζ) CAR, pCDCAR1 | Human | 219R45 | Human | scFv-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF747 | Anti-VEGF (XHM557) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | XHM557 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF749 | Anti-VEGF (219R45) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 219R45 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF802 | Anti-VEGF (XHM557) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | XHM557 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF804 | Anti-VEGF (219R45) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 219R45 | Human | scFv-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF859 | Anti-VEGF (XHM557) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | XHM557 | Mouse | scFv-CD28-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF861 | Anti-VEGF (219R45) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | 219R45 | Human | scFv-CD28-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF917 | Anti-VEGF (XHM557) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | XHM557 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF919 | Anti-VEGF (219R45) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | 219R45 | Human | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T Cell | ||
XS-0723-LX33 | Anti-cVEGF (57C) c(CD28-41BB-CD3ζ) CAR, pCDCAR1 Vector | Canine | 57C | scFv-CD28-41BB-CD4ζ | Lentiviral vector | T cell | CAR-T |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION